Triple-Drug attack aims to shrink tough colorectal tumors before surgery
NCT ID NCT07365592
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug (anti-PD-1) and a diabetes drug (sitagliptin) to standard chemotherapy can shrink tumors before surgery in people with locally advanced colorectal cancer that has a specific genetic profile (pMMR). About 138 adults aged 18–75 will receive the combination for two cycles before surgery. The goal is to see if the treatment is safe and helps reduce tumor size.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (oxaliplatin and capecitabine) plus an anti-PD-1 antibody and sitagliptin
What this could lead to
If successful, this combination could shrink tumors before surgery in patients with a hard-to-treat form of colorectal cancer, potentially improving surgical outcomes and long-term control.
What could go wrong
This is an early-phase trial (Ib/II) with a small number of participants, so results may not apply broadly. Adding more drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••